- Home
- AEF vs DCTH Comparison
AEF vs DCTH Comparison
Compare AEF & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEF | DCTH |
|---|---|---|
| Founded | 1989 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 277.7M | 350.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEF | DCTH |
|---|---|---|
| Price | $6.85 | $10.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $22.60 |
| AVG Volume (30 Days) | 92.5K | ★ 682.8K |
| Earning Date | 01-01-0001 | 11-04-2025 |
| Dividend Yield | ★ 7.13% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.57 | 0.03 |
| Revenue | N/A | ★ $79,603,000.00 |
| Revenue This Year | N/A | $131.97 |
| Revenue Next Year | N/A | $38.84 |
| P/E Ratio | ★ $8.86 | $291.54 |
| Revenue Growth | N/A | ★ 251.54 |
| 52 Week Low | $4.40 | $8.12 |
| 52 Week High | $5.53 | $18.23 |
Technical Indicators
Market Signals| Indicator | AEF | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 55.89 |
| Support Level | $6.72 | $9.84 |
| Resistance Level | $7.05 | $10.28 |
| Average True Range (ATR) | 0.12 | 0.45 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 41.82 | 57.50 |
Price Performance
Historical ComparisonAbout AEF abrdn Emerging Markets Equity Income Fund Inc.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.